Literature DB >> 10390251

In vitro susceptibilities of Chlamydia pneumoniae isolates from German patients and synergistic activity of antibiotic combinations.

H M Freidank1, P Losch, H Vögele, M Wiedmann-Al-Ahmad.   

Abstract

The susceptibilities of six Chlamydia pneumoniae type strains and of six German patient isolates to erythromycin, azithromycin, roxithromycin, clarithromycin, doxycycline, ofloxacin, and rifampin were investigated. MICs and minimal chlamydicidal concentrations were all within the ranges reported previously. Combinations of azithromycin with either ofloxacin, doxycycline, or rifampin, as well as combinations of three antibiotics (rifampin, azithromycin, and ofloxacin or doxycycline), showed synergistic activity against C. pneumoniae.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10390251      PMCID： PMC89372     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Partial characterization of Chlamydia trachomatis isolates resistant to multiple antibiotics.

Authors:  R B Jones; B Van der Pol; D H Martin; M K Shepard
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

2.  In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.

Authors:  P M Roblin; M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

3.  Susceptibility of Chlamydia pneumoniae to oral agents commonly used in the treatment of respiratory infection.

Authors:  A S Beale; N D Masson
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

Review 4.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.

Authors:  M R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

5.  In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydia.

Authors:  Y Niki; M Kimura; N Miyashita; R Soejima
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

6.  Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.

Authors:  R Malinverni; C C Kuo; L A Campbell; A Lee; J T Grayston
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.

Authors:  A Agacfidan; J Moncada; J Schachter
Journal:  Antimicrob Agents Chemother       Date:  1993-09       Impact factor: 5.191

8.  In vitro activity of rifamycins alone and in combination with other antibiotics against Chlamydia trachomatis.

Authors:  R B Jones; G L Ridgway; S Boulding; K L Hunley
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

9.  Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs. erythromycin ethylsuccinate.

Authors:  S Block; J Hedrick; M R Hammerschlag; G H Cassell; J C Craft
Journal:  Pediatr Infect Dis J       Date:  1995-06       Impact factor: 2.129

10.  The in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR).

Authors:  G L Ridgway; G Mumtaz; L Fenelon
Journal:  J Antimicrob Chemother       Date:  1991-02       Impact factor: 5.790
View more
  4 in total

1.  Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis.

Authors:  Andrei Kutlin; Stephan Kohlhoff; Patricia Roblin; Margaret R Hammerschlag; Paul Riska
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.

Authors:  Patricia M Roblin; Tamara Reznik; Andrei Kutlin; Margaret R Hammerschlag
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

3.  Chlamydia pneumoniae Infection and Inflammatory Diseases.

Authors:  Rebecca A Porritt; Timothy R Crother
Journal:  For Immunopathol Dis Therap       Date:  2016

4.  Isolation of antimicrobial resistant bacteria in upper respiratory tract infections of patients.

Authors:  Li-Min Wang; Xiao-Liang Qiao; Liang Ai; Jing-Jing Zhai; Xue-Xia Wang
Journal:  3 Biotech       Date:  2016-08-11       Impact factor: 2.406
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.